Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2024 | $169.00 | Buy | Goldman |
| 1/3/2024 | $160.00 | Outperform | Robert W. Baird |
| 11/27/2023 | $170.00 → $135.00 | Buy → Neutral | UBS |
| 9/29/2023 | Mkt Perform | Raymond James | |
| 6/12/2023 | $184.00 → $140.00 | Equal Weight | Wells Fargo |
| 12/9/2022 | $192.00 → $190.00 | Neutral → Buy | Goldman |
| 6/14/2022 | $194.00 | Buy | UBS |
| 4/6/2022 | $202.00 → $196.00 | Buy → Neutral | Goldman |
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial Company to host investor webcast on Dec. 11, 2024 For U.S. media and investors only DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treat
– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date of November 29, 2024 –– Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25 – DUBLIN, Nov. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024. "Jazz once again delivered record revenues of more than $1.05 billion and a 14% year-over-year increase in revenue from our key growth drivers combined. We continue to see robust patient demand for Xywav with approximately 400 net patient addition
DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update. Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals webs
Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short in
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Equal-Weight and lowers the price target from $160 to $150.
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized. The Role Of PBMs And Market Influence PBMs, such as UnitedHealth Group (NYSE:UNH)'s Optum, CVS Health (NYSE:CVS)'s CVS Caremark and Cigna (NYSE:CI)'s Express Scripts, negotiate discounts, create medication lists covered by insurance and reimburse pharmacies. The FTC's interim report revealed that these three PBMs manage 79% of U.S. prescription drug claims, consolidating their power and impacting dru
Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-
NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a
Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024. Peter Gray has decided not to seek re-election to the Jazz Board at the next Annual General Meeting, expected in July 2024. Mr. Kennedy's appointment reflects Jazz's ongoing focus on Board renewal, and his financial and operating expertise wi
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
10-Q - Jazz Pharmaceuticals plc (0001232524) (Filer)
8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
Goldman initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $169.00
Robert W. Baird initiated coverage of Jazz Pharma with a rating of Outperform and set a new price target of $160.00
UBS downgraded Jazz Pharma from Buy to Neutral and set a new price target of $135.00 from $170.00 previously
4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial Company to host investor webcast on Dec. 11, 2024 For U.S. media and investors only DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treat
DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT. An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days. About Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharma company whose purpose is to innovate to transform the
– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date of November 29, 2024 –– Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25 – DUBLIN, Nov. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024. "Jazz once again delivered record revenues of more than $1.05 billion and a 14% year-over-year increase in revenue from our key growth drivers combined. We continue to see robust patient demand for Xywav with approximately 400 net patient addition
For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl